Related Experiment Videos
Newer antifungal therapy for emerging fungal pathogens
William J Steinbach1, John R Perfect
1Division of Pediatric Infectious Diseases, Duke University Medical Center, Box 3499, Durham, NC 27710, USA. bill.steinbach@duke.edu
Abstract:
As the number of immunocompromised patients increases, there is a concomitant increase in the number and diversity of fungal infections. Fungi that were once considered harmless or contaminants are now pathogenic in the immunocompromised host. Often these emerging pathogens are indistinguishable from the more familiar fungal infections; however, they are generally more recalcitrant to conventional antifungal therapies. With the antifungal armamentarium now expanding, the clinician now has many more options for these difficult-to-treat mycoses. We review many of the newer antifungal agents (second-generation triazoles, echinocandins, etc.) as therapeutic options for the recently emerging fungal pathogens.
Insights
The rise in immunocompromised patients fuels diverse fungal infections. Newer antifungal drugs offer improved treatment options for these challenging, emerging fungal pathogens.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Increasing prevalence of immunocompromised individuals leads to a rise in opportunistic fungal infections.
- Emerging fungal pathogens pose significant threats, often exhibiting resistance to standard antifungal treatments.
- Traditional antifungal therapies may be less effective against newly identified or evolving fungal species.
Purpose of the Study:
- To review newer antifungal agents for treating emerging fungal pathogens.
- To provide clinicians with updated therapeutic options for difficult-to-treat mycoses.
- To highlight the expanding antifungal armamentarium in response to changing fungal infection landscape.
Main Methods:
- Literature review of emerging fungal pathogens.
- Analysis of newer antifungal agents, including second-generation azoles and echinocandins.
- Evaluation of therapeutic efficacy against recalcitrant fungal infections.
Main Results:
- Emerging fungal pathogens are increasingly common in immunocompromised hosts.
- Many new fungal infections are resistant to conventional antifungal drugs.
- Novel antifungal agents demonstrate promise in managing these difficult cases.
Conclusions:
- The expanding antifungal armamentarium provides new hope for treating complex fungal infections.
- Clinicians must stay informed about emerging pathogens and novel therapeutic strategies.
- Advances in antifungal therapy are crucial for managing the growing burden of fungal diseases.